Department of Pediatrics - Section of Hematology/Oncology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA.
Edward B. Singleton Department of Radiology, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, USA.
Pediatr Blood Cancer. 2021 Jul;68(7):e29056. doi: 10.1002/pbc.29056. Epub 2021 Apr 12.
Neuroendocrine tumors (NETs) of the pancreas and midgut are extremely rare in children, and patients presenting with metastatic disease have poor survival. Given this rarity, treatments are extrapolated from guidelines for adults with NET. Recent clinical trials in adults with NETs have shown that the addition of peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE resulted in a disease control rate of nearly 80%, with minimal side effects. We report our experience using Lu-DOTATATE to treat two pediatric patients with metastatic NET.
胰腺和中肠的神经内分泌肿瘤（NET）在儿童中极为罕见，患有转移性疾病的患者生存状况较差。鉴于这种罕见性，治疗方法是从成人 NET 指南中推断出来的。最近针对成人 NET 的临床试验表明，添加肽受体放射性核素治疗（PRRT）与 Lu-DOTATATE 联合使用可使疾病控制率接近 80%，且副作用极小。我们报告了使用 Lu-DOTATATE 治疗 2 例转移性 NET 儿科患者的经验。
